Tag Archives: Sorrento

November, 2018

7 November
Sorrento’s Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity with Increased Overall Survival in Pancreatic Cancer Patients with Liver Metastases

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”) announced today the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery (PEDD) manufactured by TriSalus™ Life Sciences. The preliminary data for the Hepatic Immunotherapy for …
Share

5 July
Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immuno-Oncology Antibody Therapeutics

SAN DIEGO, July 03, 2018 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ:SRNE) (“Sorrento”) announced today that it acquired the Sofusa™ lymphatic delivery technology platform from Kimberly-Clark Corporation for targeted biopharmaceuticals, particularly, the immune checkpoint inhibitors (such as anti-PD-1, CTLA4, CD47 antibodies) and other I-O antibodies. Pioneered by inventor Dr. Russell F. …
Share